Technical Data
Interleukin 1 alpha, Recombinant, Human (IL-1a, Hematopoietin-1, Lymphocyte-activating Factor, LAF, Endogenous Pyrogen, Leukocyte Endogenous Mediator, LEM, Mononuclear Cell Factor, MCF)
Molecular Biology Storage: -20CShipping: RT
A soluble factor produced by monocytes, macrophages, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. IL-1 consists of two distinct forms, IL-1 alpha and IL-1 beta which perform the same functions but are distinct proteins. The synthesis of IL-1 can be induced by other cytokines including TNF-alpha, IFN-alpha, IFN-beta and IFN-g and also by bacterial endotoxins, viruses, mitogens, and antigens. In human skin fibroblasts IL1-alpha and TNF-alpha induce the synthesis of IL1-beta. In pheochromocytoma cells, NGF induces the synthesis of IL1.

Recombinant Human IL-1 is a single, non-glycosylated, Polypeptide chain containing 159 amino acids and having a molecular mass of 18022 Dalton.

The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Ala-Pro-Phe-Ser.

Dimers and Aggregates:
1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:
rHuIL-1alpha is fully biologically active when compared to standards. The ED50 as determined by the dose-dependent stimulation of murine D10S cells is less then 0.001ng/ml, corresponding to a Specific Activity of 1 x 10e6 IU/mg.

0.1ng/ug (IEU/ug)

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm using the absorbency value of 1.13 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a standard solution of chicken IL-1alpha as a Reference Standard.

Reconstitute the lyophilized rHuIL-1alpha in sterile 18M -cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Storage and Stability:
Lyophilized powder is stable for at least 12 months at -20C Reconstituted product must be stored in aliquots at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Source: E. coli
Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.
Concentration: ~0.1mg/ml
Form: Supplied as a lyophilized powder in 20mM Tris-HCl, pH 8.0, 5mM MgCl2, 10% glycerol.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Effect of early luteal phase administration of a single dose mifepristone on immunohistochemical distribution of interleukin 1 alpha (IL-1 alpha) and transforming growth factor beta 1 (TGF-beta 1) in mid-luteal phase ovary of the rhesus monkey. Sengupta S, Ghosh D, Indian J Physiol Pharmacol 2003 Apr;47(2):221-4 2. [Analysis on association between the polymorphisms in apolipoprotein E, interleukin-1 alpha genes and Alzheimer's disease in Chengdu area] Tang MN, Zhang ZX, Liu XH, Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2004 Apr;21(2) :176-8 3. [Content of tumor necrosis factor alpha and interleukin 1-alpha in patients with acute purulent pleural cavity] Snizhko SS, Klin Khir 2003 Dec;(12):26-8 4. Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease. Moller JC, Depboylu C, Lohmuller F, Paus S, Neurosci Lett 2004 Apr 15;359(3):195-7 5. The paracrine role played by interleukin-1 alpha in the testis. Svechnikov K, Petersen C, Wahlgren A, Soder O, Curr Drug Targets Immune Endocr Metabol Disord 2004 Mar;4(1):67-74 6. Imiquimod-induced interleukin-1 alpha stimulation improves barrier homeostasis in aged murine epidermis. Barland CO, Zettersten E, Ye J, J Invest Dermatol 2004 Feb;122(2):330-6.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.